Biogen Idec/Samsung's biologics JV begins life as Samsung Bioepis
This article was originally published in Scrip
Biogen Idec and Samsung Biologics have now formally established their South Korean joint venture for biologics following the basic agreement for the $300 million operation reached in December.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.